Foamix Pharmaceuticals Company Profile (NASDAQ:FOMX)

About Foamix Pharmaceuticals

Foamix Pharmaceuticals logoFoamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations. The Company develops FMX101, FMX102, FMX103 and FDX104 using its technology, which includes foam-based platforms. The Company's lead product candidate FMX101, is a novel topical foam formulation of the antibiotic minocycline. The Company develops FMX102, a minocycline foam product candidate for the treatment of impetigo, including cases of impetigo caused by methicillin-resistant staphylococcus aureus (MRSA). It is also developing FMX103, minocycline foam for rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It completed a Phase II clinical trial for FMX102.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FOMX
  • CUSIP:
Key Metrics:
  • Previous Close: $9.83
  • 50 Day Moving Average: $9.05
  • 200 Day Moving Average: $7.30
  • 52-Week Range: $5.48 - $10.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.86
  • P/E Growth: 0.00
  • Market Cap: $301.40M
  • Outstanding Shares: 30,661,000
  • Beta: 1.42
Profitability:
  • Net Margins: -1,201.01%
  • Return on Equity: -21.87%
  • Return on Assets: -21.08%
Debt:
  • Current Ratio: 26.33%
  • Quick Ratio: 26.33%
Additional Links:
Companies Related to Foamix Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Foamix Pharmaceuticals (NASDAQ:FOMX) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.00 (103.46% upside)
Analysts' Ratings History for Foamix Pharmaceuticals (NASDAQ:FOMX)
Show:
DateFirmActionRatingPrice TargetDetails
8/13/2016GuggenheimReiterated RatingBuy$10.00 -> $20.00View Rating Details
3/16/2015Barclays PLCBoost Price TargetOverweight$11.00 -> $15.00View Rating Details
11/18/2014MacquarieInitiated CoverageNeutralView Rating Details
11/18/2014Maxim GroupInitiated CoverageHold$38.00View Rating Details
10/13/2014Cowen and CompanyInitiated CoverageOutperform$30.00View Rating Details
10/13/2014Oppenheimer Holdings Inc.Initiated CoverageOutperform$15.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/10/2016Q216($0.25)($0.27)$1.10 million$1.50 millionViewListenView Earnings Details
5/10/2016Q1($0.23)($0.15)ViewListenView Earnings Details
11/11/2015Q315($0.20)($0.11)ViewListenView Earnings Details
8/19/2015Q215($0.14)($0.18)ViewListenView Earnings Details
5/12/2015Q1($0.12)($0.14)ViewN/AView Earnings Details
4/15/2015($0.12)($0.18)ViewN/AView Earnings Details
3/18/2015($0.05)($0.01)ViewN/AView Earnings Details
11/14/2014Q314($0.07)($0.61)$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Foamix Pharmaceuticals (NASDAQ:FOMX)
Current Year EPS Consensus Estimate: $-0.87 EPS
Next Year EPS Consensus Estimate: $-1.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.23)($0.23)($0.23)
Q2 20161($0.22)($0.22)($0.22)
Q3 20161($0.20)($0.20)($0.20)
Q4 20161($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Foamix Pharmaceuticals (NASDAQ:FOMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Foamix Pharmaceuticals (NASDAQ:FOMX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Foamix Pharmaceuticals (NASDAQ:FOMX)
DateHeadline
finance.yahoo.com logoCan The Uptrend Continue for Foamix Pharmaceuticals (FOMX)? (NASDAQ:FOMX)
finance.yahoo.com - September 21 at 9:19 AM
benzinga.com logoFoamix Announces Positive Topline Results from... (NASDAQ:FOMX)
www.benzinga.com - September 17 at 9:46 AM
finance.yahoo.com logoInside the Recent Surge in Biotech ETFs (NASDAQ:FOMX)
finance.yahoo.com - September 14 at 5:06 PM
News IconM&A Activity, Passing Drug Trials Help Biotech ETFs Rebound (NASDAQ:FOMX)
www.etftrends.com - September 12 at 4:54 PM
rttnews.com logoHere's Why You Need To Watch FOMX Today... (NASDAQ:FOMX)
www.rttnews.com - September 12 at 4:54 PM
finance.yahoo.com logoFoamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam … (NASDAQ:FOMX)
finance.yahoo.com - September 12 at 4:54 PM
schaeffersresearch.com logo2 Biotech Stocks Burning Short Sellers (NASDAQ:FOMX)
www.schaeffersresearch.com - September 12 at 4:54 PM
News IconFoamix Pharmaceuticals Ltd (NASDAQ:FOMX): Our Swing Trading Pick Rocked With 26% Profit In No Time (NASDAQ:FOMX)
www.marketnewscall.com - September 12 at 4:54 PM
marketwatch.com logoBiotech ETF gets a lift from Raptor deal, Foamix drug trial (NASDAQ:FOMX)
www.marketwatch.com - September 12 at 4:54 PM
finance.yahoo.com logo7:01 am Foamix topline results from phase 2 trial evaluating FMX-103 topical minocycline foam for moderate-to-severe papulopustular rosacea (NASDAQ:FOMX)
finance.yahoo.com - September 12 at 9:54 AM
publicnow.com logoFoamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea (NASDAQ:FOMX)
www.publicnow.com - September 12 at 9:54 AM
publicnow.com logoFoamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea (NASDAQ:FOMX)
www.publicnow.com - September 9 at 9:50 AM
finance.yahoo.com logoFoamix to Present Corporate Overview at the Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:FOMX)
finance.yahoo.com - September 6 at 9:51 AM
zacks.com logoHow Foamix (FOMX) Stock Stands Out in a Strong Industry (NASDAQ:FOMX)
www.zacks.com - August 29 at 9:42 AM
finance.yahoo.com logoWill Foamix Pharmaceuticals (FOMX) Continue to Surge Higher? (NASDAQ:FOMX)
finance.yahoo.com - August 16 at 5:11 PM
capitalcube.com logoFoamix Pharmaceuticals Ltd. :FOMX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:FOMX)
www.capitalcube.com - August 12 at 5:07 PM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 10-Aug-16 12:30pm GMT (NASDAQ:FOMX)
finance.yahoo.com - August 10 at 11:14 PM
schaeffersresearch.com logoAnalyst Update: Foamix Pharmaceuticals Ltd, Jazz Pharmaceuticals plc, and Healthways, Inc. (NASDAQ:FOMX)
www.schaeffersresearch.com - August 10 at 5:17 PM
sg.finance.yahoo.com logoFoamix reports 2Q loss (NASDAQ:FOMX)
sg.finance.yahoo.com - August 10 at 12:30 PM
publicnow.com logoFoamix Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:FOMX)
www.publicnow.com - August 10 at 12:30 PM
publicnow.com logoFoamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for Wednesday, August 10 (NASDAQ:FOMX)
www.publicnow.com - July 25 at 8:18 AM
capitalcube.com logoETF’s with exposure to Foamix Pharmaceuticals Ltd. : June 24, 2016 (NASDAQ:FOMX)
www.capitalcube.com - June 24 at 5:32 PM
publicnow.com logoFoamix to Present at the BIO International Convention (NASDAQ:FOMX)
www.publicnow.com - June 1 at 8:23 AM
benzinga.com logoFoamix Pharmaceuticals Announces Publication of Abstract on FDX-104 for the 2016 ASCO Meeting - Benzinga (NASDAQ:FOMX)
www.benzinga.com - May 31 at 11:19 AM
publicnow.com logoFoamix Pharmaceuticals Announces Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash for the 2016 ASCO Meeting (NASDAQ:FOMX)
www.publicnow.com - May 31 at 8:12 AM
News IconFoamix Pharmaceuticals Limited Ord (NASDAQ:FOMX) Sellers Increased By 1.45% Their Shorts - Wall Street Hints and News (NASDAQ:FOMX)
hintsnewsnetwork.com - May 26 at 11:48 AM
capitalcube.com logoFoamix Pharmaceuticals Ltd. :FOMX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 (NASDAQ:FOMX)
www.capitalcube.com - May 26 at 11:19 AM
publicnow.com logoFoamix to Present Corporate Overview at the Jefferies 2016 Healthcare Conference (NASDAQ:FOMX)
www.publicnow.com - May 26 at 8:27 AM
publicnow.com logoFoamix Names Dr. Stanley Hirsch as Chairman, and Dr. Dalia Megiddo as a Member of the Board of Foamix Pharmaceuticals (NASDAQ:FOMX)
www.publicnow.com - May 16 at 8:32 AM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 10-May-16 12:00pm GMT (NASDAQ:FOMX)
finance.yahoo.com - May 10 at 4:13 PM
biz.yahoo.com logoQ1 2016 Foamix Pharmaceuticals Ltd Earnings Release - Before Market Open (NASDAQ:FOMX)
biz.yahoo.com - May 10 at 7:07 AM
publicnow.com logoFoamix Reports First Quarter 2016 Financial Results and Provides Business Update (NASDAQ:FOMX)
www.publicnow.com - May 10 at 6:18 AM
sg.finance.yahoo.com logoFoamix reports 1Q loss (NASDAQ:FOMX)
sg.finance.yahoo.com - May 10 at 6:16 AM
publicnow.com logoFoamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101 (NASDAQ:FOMX)
www.publicnow.com - May 9 at 7:26 AM
publicnow.com logoFoamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea (NASDAQ:FOMX)
www.publicnow.com - May 3 at 8:20 AM
News IconChanges To Broker Targets On Foamix Pharmaceuticals Ltd. (FOMX) - Share Trading News (NASDAQ:FOMX)
www.sharetrading.news - February 26 at 12:35 PM
finance.yahoo.com logoFoamix Pharmaceuticals Fourth Quarter and Fiscal Year 2015 Financial Results Conference Call & Webcast Scheduled for Thursday, March 3 (NASDAQ:FOMX)
finance.yahoo.com - February 18 at 8:00 AM
News IconFoamix Pharmaceuticals Limited Ord (NASDAQ:FOMX) Shorted Shares Decreased By 10.09% - fdanewsalert.com (NASDAQ:FOMX)
www.fdanewsalert.com - February 14 at 2:08 PM
News IconAnalyst Coverage Updates - Foamix Pharmaceuticals Ltd. (FOMX) - Risers & Fallers (NASDAQ:FOMX)
www.risersandfallers.com - February 3 at 1:49 PM
News IconCompany Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Drops by -10.13% - Bull Report (NASDAQ:FOMX)
www.bullreport.news - February 1 at 1:43 PM
investornewswire.com logoSentiment And Earnings Update For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) - Investor Newswire (NASDAQ:FOMX)
www.investornewswire.com - January 28 at 1:40 PM
thestreet.com logoFoamix Pharmaceuticals Enters Oversold Territory (FOMX) (NASDAQ:FOMX)
www.thestreet.com - January 28 at 1:40 PM
News IconFoamix Pharmaceuticals Ltd. (FOMX) Recent Analyst Updates - Risers & Fallers (NASDAQ:FOMX)
www.risersandfallers.com - January 26 at 1:46 PM
News IconCompany Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Rally 2.41% - The Daily Rover (NASDAQ:FOMX)
thedailyrover.com - January 25 at 1:01 PM
finance.yahoo.com logoFoamix Pharmaceuticals Ltd. (FOMX) (NASDAQ:FOMX)
finance.yahoo.com - January 21 at 12:54 PM
finance.yahoo.com logoFOAMIX PHARMACEUTICALS LTD. Financials (NASDAQ:FOMX)
finance.yahoo.com - December 8 at 1:07 PM
fool.com logoFoamix Pharmaceuticals Ltd Hopes to Profit From Eli Lilly's and Amgen's Side Effect (NASDAQ:FOMX)
www.fool.com - December 3 at 1:34 PM
insidermonkey.com logoHere Is Why Investors Are Pushing Foamix Pharmaceuticals Ltd (FOMX) Higher Today (NASDAQ:FOMX)
www.insidermonkey.com - December 3 at 1:17 PM
finance.yahoo.com logoFoamix Soars on Positive Phase 2 Results (NASDAQ:FOMX)
finance.yahoo.com - December 3 at 12:10 PM
finance.yahoo.com logoFoamix Announces Positive Top-Line Results From Phase II Study for FDX104 (Doxycycline Foam) in the Prevention of Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers (NASDAQ:FOMX)
finance.yahoo.com - December 3 at 7:00 AM

Social

Foamix Pharmaceuticals (NASDAQ:FOMX) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff